Furthermore, it has been reported that NGI-1 can effectively block EGFR signal transduction by inhibiting N-glycosylation of EGFR in tyrosine kinase inhibitor (TKI) resistance non-small cell lung cancer (NSCLC), leading to cell-cycle arrest and proliferative block [82]. Here, EGFR is linked to non-small cell lung carcinoma.